Abstract
Those immunoconjugates that have entered clinical trials (i.e., immunotoxins, radiolabelled and bispecific antibodies) have shown promising antitumour activity in haematopoietic tumours (lymphomas/leukaemias). To eliminate large solid tumours, immunoconjugates will require changes in both the antibody and effector moieties since these tumours are poorly vascularised and rarely express tumour-specific antigens. This review describes improvements which may have a major impact on the next generation of immunoconjugates.
Original language | English (US) |
---|---|
Pages (from-to) | 309-321 |
Number of pages | 13 |
Journal | Expert Opinion on Investigational Drugs |
Volume | 5 |
Issue number | 3 |
DOIs | |
State | Published - 1996 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)